Volltext-Downloads (blau) und Frontdoor-Views (grau)
The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 2 of 3
Back to Result List

Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus

  • Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP). Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, β-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes [2146 male, 2124 female; mean age ±SD, 63.9±11.1years; body mass index (BMI) 30.1±5.5kg/m2; disease duration 5.4±5.6years; hemoglobin A1c (HbA1c) 6.8±1.3%]. It consisted of a single morning visit with collection of a fasting blood sample. Observational parameters included several clinical scores and laboratory biomarkers. Results: Stratification into cardiovascular risk groups according to hsCRP levels revealed that 934 patients had low risk (hsCRP <1mg/L), 1369 patients had intermediate risk (hsCRP 1–3mg/L), 1352 patients had high risk (hsCRP >3–10mg/L), and 610 patients had unspecific hsCRP elevation (>10mg/L). Increased hsCRP levels were associated with other indicators of diabetes-related cardiovascular risk (homeostatic model assessment, intact proinsulin, insulin, BMI, β-cell dysfunction, all p<0.001), but showed no correlation with disease duration or glucose control. The majority of the patients were treated with diet (34.1%; hsCRP levels 2.85±2.39mg/L) or metformin monotherapy (21.1%; 2.95±2.50mg/L hsCRP). The highest hsCRP levels were observed in patients treated with sulfonylurea (17.0%; 3.00±2.43mg/L). Conclusions: Our results indicate that hsCRP may be used as a cardiovascular risk marker in patients with type 2 diabetes mellitus and should be evaluated in further prospective studies.

Download full text files

Export metadata

Additional Services

Search Google Scholar Check availability

Statistics

Show usage statistics
Metadaten
Document Type:Article
Language:English
Author:Andreas Pfützner, Eberhard Standl, Hermann-Josef Strotmann, Jan Schulze, Cloth Hohberg, Georg Lübben, Sabine Pahler, Thomas Schöndorf, Thomas Forst
Parent Title (English):Clinical Chemistry and Laboratory Medicine
Volume:44
Issue:5
First Page:556
Last Page:560
ISSN:1437-4331
URN:urn:nbn:de:hbz:1044-opus-28723
DOI:https://doi.org/10.1515/CCLM.2006.108
PMID:https://pubmed.ncbi.nlm.nih.gov/16681424
Publisher:de Gruyter
Place of publication:Berlin
Publishing Institution:Hochschule Bonn-Rhein-Sieg
Date of first publication:2006/05/01
Embargo Date:2007/05/01
Copyright:©2006 by Walter de Gruyter Berlin New York. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
Keyword:high-sensitivity C-reactive protein (hsCRP); homeostatic model assessment (HOMA); insulin resistance; intact proinsulin; type 2 diabetes
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Open access funding:Deutsche Forschungsgemeinschaft / Allianz- und Nationallizenzen: Diese Beiträge sind mit Zustimmung der Rechteinhaber aufgrund einer DFG-geförderten National- bzw. Allianzlizenz frei zugänglich.
Entry in this database:2017/01/25
Licence (Multiple languages):License LogoIn Copyright (Urheberrechtsschutz)